8.6 Guideline-Directed Medical Therapy for Heart Failure

The Four Pillars and Why Speed Now Matters More Than Sequence

Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF, ejection fraction 40% or less) rests on four foundational drug classes in the 2022 AHA/ACC/HFSA guideline. Each carries an independent mortality benefit, the benefits are largely additive, and much of the benefit appears within the first 30 days of therapy. Comprehensive four-class therapy is estimated to add several years of event-free survival compared with an angiotensin-converting enzyme (ACE) inhibitor and beta blocker alone.

The modern practice change is rapid sequential initiation: get all four classes on board at low doses within days, then up-titrate every 1-2 weeks, rather than maximizing one agent before starting the next. Trial evidence supports intensive in-hospital initiation with up-titration toward full doses within about two weeks of discharge and close follow-up, which reduced 180-day readmission and death. The clinical corollary for nurses is that "the patient is not on the target dose yet" is far less concerning than "the patient is only on one pillar."

The ARNI Details the Exam Tests

Sacubitril/valsartan combines a neprilysin inhibitor with an ARB and is preferred over an ACE inhibitor or ARB in NYHA class II-III HFrEF. It may be started in hospital once the patient is hemodynamically stable, off intravenous inotropes and vasodilators, and with a systolic pressure at or above 100 mmHg.

The 36-hour washout rule. When switching from an ACE inhibitor, the ACE inhibitor must be held for 36 hours before the first sacubitril/valsartan dose. Both drugs impair bradykinin degradation - ACE inhibition blocks its breakdown and neprilysin inhibition blocks another degradation pathway - so overlapping them stacks bradykinin and produces angioedema. No washout is required when switching from an ARB, because ARBs do not affect bradykinin. A prior history of angioedema on any agent is an absolute contraindication. Also avoid in pregnancy and with aliskiren in diabetes.

Beta Blocker Initiation Rules

Only carvedilol, metoprolol succinate, and bisoprolol have mortality evidence in HFrEF. Metoprolol tartrate is not an acceptable substitute. Initiate only in a patient who is euvolemic, not inotrope-dependent, and not in an escalating diuretic phase, then double no more often than every two weeks. Warn the patient and the team about the expected transient early worsening - fatigue, mild weight gain, and slightly worse symptoms over the first 2-6 weeks - which is managed by increasing the diuretic, not by abandoning the beta blocker. Conversely, do not routinely stop a chronic beta blocker during an admission for decompensation; abrupt withdrawal is associated with higher mortality. Discontinue only for cardiogenic shock, inotrope dependence, symptomatic bradycardia, or high-grade block.

Monitoring, Thresholds and Adverse Effects

After starting or increasing an ACE inhibitor, ARB, ARNI, or MRA, check a basic metabolic panel in 1-2 weeks; for an MRA, check at 2-3 days and again at 7 days, then monthly for three months, then quarterly.

• Creatinine. A rise of up to 30% above baseline after renin-angiotensin system blockade is expected, reflects reduced intraglomerular pressure, and is not a reason to stop the drug. A rise beyond 30%, or any rise with hypotension, should prompt a search for volume depletion, over-diuresis, NSAIDs, or another nephrotoxin before the GDMT is reduced.
• Potassium. Hold or reduce for a potassium above 5.5 mEq/L. Manage hyperkalemia by stopping potassium supplements and potassium-containing salt substitutes, restricting dietary potassium, correcting acidosis, reducing the MRA dose, and using a potassium binder such as patiromer or sodium zirconium cyclosilicate to keep the patient on therapy. The goal is to preserve GDMT, not to abandon it at the first elevated value.
• Symptomatic hypotension. Reduce or space the diuretic first, then remove non-essential blood-pressure-lowering drugs (calcium channel blockers, nitrates, alpha blockers), then separate the dosing times of the pillars, and only then reduce GDMT. An asymptomatic systolic pressure in the 85-90 mmHg range is not by itself a reason to reduce therapy.
• SGLT2 inhibitors. Counsel on genital mycotic infection and perineal hygiene. Recognize euglycemic diabetic ketoacidosis - ketoacidosis with a glucose that may be under 250 mg/dL, presenting as nausea, abdominal pain, and an anion-gap acidosis. Hold the drug for 3-4 days before major surgery and during prolonged NPO status or acute illness with poor intake. Expect a small early decline in eGFR of about 3-5 mL/min over the first 2-4 weeks, which is hemodynamic and not a reason to stop.
• MRA contraindications. Do not initiate with an eGFR below 30 mL/min/1.73 m2 or a potassium above 5.0 mEq/L. Switch spironolactone to eplerenone for gynecomastia or breast tenderness.

Adjunctive and Second-Line Therapy

Hydralazine plus isosorbide dinitrate. A Class 1 recommendation for self-identified Black patients with NYHA class III-IV HFrEF already on optimal GDMT, and a reasonable option for any patient who cannot tolerate an ACE inhibitor, ARB, or ARNI because of renal insufficiency or hyperkalemia. Start hydralazine 25-37.5 mg three times daily with isosorbide dinitrate 20-40 mg three times daily; target 75 mg and 40 mg three times daily. Adherence is the limitation - three-times-daily dosing, headache, and a hydralazine-associated lupus-like syndrome.

Ivabradine. Selectively inhibits the funny current in the sinoatrial node, slowing rate without any inotropic effect. Indicated for symptomatic stable chronic HFrEF with an ejection fraction of 35% or less, in sinus rhythm, with a resting heart rate of 70 beats per minute or more on a maximally tolerated beta blocker (or with a documented beta blocker contraindication). Start 5 mg twice daily, or 2.5 mg twice daily in patients over 75 or with conduction disease, and titrate to a resting rate of 50-60, maximum 7.5 mg twice daily. It does nothing in atrial fibrillation. Side effects include bradycardia, an increased incidence of atrial fibrillation, and phosphenes - transient luminous visual brightness - in about 3%. Verify sinus rhythm on an actual 12-lead ECG before dosing, not from the monitor label.

Vericiguat. An oral soluble guanylate cyclase stimulator for patients with an ejection fraction below 45% and a recent worsening heart failure event - hospitalization within 6 months or IV diuretic within 3 months - who are already on GDMT. Titrate 2.5 mg daily to 5 mg to 10 mg daily at 2-week intervals. Hold for a systolic pressure below 100 mmHg. Contraindicated with phosphodiesterase-5 inhibitors and with riociguat.

Digoxin. A Class 2b agent that reduces heart failure hospitalization without a mortality benefit. Target a serum concentration of 0.5-0.9 ng/mL in heart failure; higher levels are associated with harm. Draw the level at least 6-8 hours after the dose. The "scooped" or sagging ST depression is the digoxin effect, not toxicity. Toxicity presents as anorexia, nausea, confusion, and visual halos or yellow-green color disturbance, with characteristic rhythms including atrial tachycardia with block, junctional tachycardia, bidirectional ventricular tachycardia, a regularized ventricular response in atrial fibrillation, and any bradyarrhythmia. Toxicity is potentiated by hypokalemia, hypomagnesemia, hypercalcemia, hypothyroidism, and renal impairment. Interacting drugs that raise levels include amiodarone (halve the dose), verapamil, dronedarone, propafenone, quinidine, clarithromycin, itraconazole, cyclosporine, and spironolactone. The antidote is digoxin immune Fab.

Intravenous iron. For iron deficiency defined as ferritin below 100 ng/mL, or ferritin 100-299 ng/mL with a transferrin saturation below 20%, in NYHA class II-III HFrEF, ferric carboxymaltose or ferric derisomaltose improves symptoms, functional capacity, and quality of life. Oral iron is ineffective in heart failure. Monitor for infusion reactions and, with ferric carboxymaltose, for hypophosphatemia.

HFpEF: A Different Therapeutic Ladder

Heart failure with preserved ejection fraction (ejection fraction 50% or greater) does not share the four-pillar structure. Diuretics for congestion remain a Class 1 recommendation, and SGLT2 inhibitors carry the strongest disease-modifying recommendation, with mineralocorticoid receptor antagonists, ARNI, and ARBs supported more weakly and generally favored at the lower end of the preserved range. Beta blockers have no mortality benefit here and can worsen chronotropic incompetence and exercise capacity. The higher-yield work in HFpEF is treating what drives it: hypertension, atrial fibrillation, obesity, coronary disease, chronic kidney disease, and sleep apnea - plus screening for cardiac amyloidosis when there is unexplained wall thickening, low-voltage ECG with hypertrophy on echocardiography, bilateral carpal tunnel syndrome, or intolerance of standard heart failure drugs.

Medications to Avoid or De-Escalate

The Nurse's Role in Titration and Adherence

Nurse-led titration clinics measurably improve the proportion of patients reaching target doses, and the up-titration decision is a nursing assessment before it is a prescribing one. Run the same checklist at every visit or every shift: sitting and standing blood pressure and heart rate, weight trend, jugular venous pressure and edema, orthopnea and exertional tolerance, the most recent potassium and creatinine, and symptom-limited tolerance of the current regimen.

Then apply two stopping rules. A patient who is too hypotensive - symptomatic dizziness or presyncope, or a systolic pressure below 90 mmHg with symptoms - is not a candidate for advancement until diuretics and non-essential antihypertensives have been trimmed. A patient who is too congested - rising weight, new orthopnea, rising jugular venous pressure - should have the diuretic addressed before the beta blocker is increased, because beta blockade in a wet patient reliably makes them wetter.

Adherence deserves the same rigor as titration. Three of the four pillars are commonly branded and expensive, so verify affordability and fill status before discharge, not at the first follow-up. Teach the patient which symptoms mean "call" versus "hold": a weight gain of 2-3 pounds overnight or 5 pounds in a week, new orthopnea or paroxysmal nocturnal dyspnea, dizziness on standing, or palpitations. Reinforce sodium restriction to roughly 2-3 g per day, the prohibition on NSAIDs and on potassium-containing salt substitutes, and the fact that feeling worse for a few weeks after a beta blocker increase is expected rather than a reason to stop. Use teach-back, give a written titration schedule, and document the current dose of every pillar in the handoff so the next clinician knows what is left to advance.